Mannitolo Monico (Mannitol)

Mannitol is used in clinical settings to manage conditions that involve excess fluid accumulation or elevated pressure within the central nervous system and the eye.

• Cerebral edema: reduces brain swelling by lowering intracranial pressure.
• Increased intracranial pressure: rapidly decreases pressure to protect neural tissue.
• Acute glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage.
• Renal failure with oliguria: promotes osmotic diuresis to improve urine output.

• After intravenous administration, mannitol remains largely extracellular because it is not readily metabolized. It creates an osmotic gradient across the renal tubular membrane, drawing water into the tubular lumen and increasing urine volume. The same gradient in the vascular and interstitial compartments pulls fluid out of edematous brain or ocular tissues, thereby reducing intracranial and intra‑ocular pressure.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate discomfort often transient.
• Nausea or vomiting: gastrointestinal upset following infusion.
• Electrolyte imbalance: changes in sodium or potassium levels.
• Hypotension: drop in blood pressure during rapid infusion.

Serious or Rare Side Effects

• Pulmonary edema: fluid accumulation in the lungs, potentially life‑threatening.
• Acute renal failure: worsening kidney function in susceptible patients.
• Hemolysis: destruction of red blood cells, especially in patients with G6PD deficiency.

When using Mannitol, clinicians should observe several precautionary measures to minimize risks.

• Monitor fluid balance: assess input and output closely during therapy.
• Check serum electrolytes: evaluate sodium, potassium, and osmolality before and during treatment.
• Assess renal function: measure creatinine and urine output to ensure adequate clearance.
• Avoid rapid infusion in heart failure: infuse slowly to prevent cardiovascular overload.
• Use with caution in pregnancy: safety data are limited, weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Loop diuretics (e.g., furosemide): combined use may cause excessive diuresis and electrolyte loss.
• Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): concurrent therapy can increase risk of renal impairment.

Moderate Interactions (Monitor Closely)

• Insulin: rapid shifts in plasma osmolality may affect glucose control, requiring monitoring.
• ACE inhibitors or ARBs: may potentiate hypotensive effects when mannitol is infused quickly.
• Anticoagulants (e.g., warfarin): volume shifts can influence coagulation parameters, necessitating periodic INR checks.